Karl Fagerström occupies a distinctive position in the nicotine research field. As the developer of the Fagerström Test for Nicotine Dependence — the primary clinical instrument for assessing nicotine dependence severity — he has spent decades examining the mechanisms of addiction, the effectiveness of cessation approaches, and the potential role of alternative products in harm reduction. His views on nicotine pouches are therefore worth understanding in some depth.
Fagerström’s position on nicotine is more nuanced than the binary debate between prohibition and harm reduction advocates sometimes suggests. He argues that nicotine dependence is real and should be taken seriously, but that its health consequences depend almost entirely on the delivery mechanism. Nicotine itself, delivered through clean mechanisms, is not the primary cause of tobacco-related disease. The combustion products, the tobacco nitrosamines, the tar — these are the killers. Separating nicotine from tobacco combustion is therefore a meaningful public health goal.
On pouches specifically, Fagerström has been relatively positive, noting that they represent one of the cleanest delivery mechanisms available for nicotine. The absence of tobacco leaf, the absence of combustion, the relatively short contact period with oral tissues — these characteristics compare favourably with virtually all other nicotine delivery systems that are currently available at scale. He is careful to note that long-term safety data is limited, but his reading of the mechanistic evidence is that serious concern about pouches — at normal use rates — is not well-supported.
His concern about the current policy environment is that the precautionary principle is being applied asymmetrically. Cigarettes — with their well-documented catastrophic health consequences — remain available with minimal restriction beyond age limits and packaging requirements. Alternative products that present a fraction of that risk face intense regulatory scrutiny. This asymmetry, he argues, is not defensible on a pure risk-proportionality basis.
The Fagerström perspective does not resolve all the contested questions in nicotine policy. But it offers a grounding in the dependency science that much commentary on this topic lacks, and it comes from someone whose professional commitment has been to understanding nicotine as it actually is rather than as it is politically convenient to frame it.
